and risk stratification of ARDS. Although various biomarkers, such as surfactant protein-D (SP-D), soluble receptor for advanced glycation end-products (sRAGE), and Krebs von den Lungen (KL-6), have been investigated for possible use in ARDS diagnosis, their clinical utility is limited due to the lack of discriminatory power. 5 Club cell protein (CC16), an anti-inflammatory protein mainly produced and secreted by the Club cells in the distal respiratory or terminal bronchioles, has been proposed as a biomarker for lung epithelial injury. 6 Considering the large blood-tissue exchange surface area of lung tissues, serum CC16 is almost solely derived from the respiratory tract and is, therefore, considered lung-specific. Increased circulating CC16 levels have been observed in patients with pulmonary injuries caused by inhaled ozone, chlorine, and LPS. [7] [8] [9] It has been suggested as a disease marker for pulmonary sarcoidosis, chronic obstructive pulmonary disease, and severe chest trauma. [10] [11] [12] However, whether the CC16 levels can be used in ARDS diagnosis, classification, and outcome prediction remains unclear, although a few clinical studies have indicated that circulating CC16 levels are associated with the development of ARDS. 13 In this study, we investigated the serum levels of CC16 in patients with and without ARDS in order to test our hypothesis that serum CC16 may help distinguish and stratify ARDS patients, correlated with the prognostic parameters such as survival and length of hospital stay. Our results have clinical implications for ARDS management.
| METHODS

| Patients and study design
This study was reviewed and approved by the Ethics Committee of Baoan Hospital of Nanfang Medical University, and a written informed consent was obtained from each of the participants or their legal surrogates.
The study retrospectively analyzed 212 patients who were consecutively admitted into our comprehensive intensive care unit (ICU) All patients meeting the above ARDS criteria were included in this study. The exclusion criteria were as follows: (i) patients with acute or chronic renal dysfunction, congestive heart failure, or a myocardial infarction within 30 days prior to enrollment; (ii) patient's age was less than 18 years or more than 80 years; and (iii) pregnant patients.
All enrolled patients were followed up for 28 days. A radiologist, blinded to the clinical phenotype and CC16 measurement, reviewed radiographs.
| Laboratory examination
Blood samples were drawn from the radial artery within 2 hours of ICU admission; the analyses included white blood cell count (WBC), C-reactive protein (CRP), the N-terminal of the prohormone brain natriuretic peptide (NT-proBNP), albumin, and serum creatinine (Scr).
For the measurement of CC16, the blood samples were immediately centrifuged at 1580 g for 10 minutes, and the serum was stored at −60°C until analysis. CC16 concentration was determined using ELISA kits (R&D Systems, Minneapolis, MN, USA) following the manufacturer's instructions. Each assay was performed in duplicate. The laboratory staff who performed the analyses were blinded to clinical phenotypes.
| Data processing and statistical analysis
The 
T A B L E 1 Characteristics of ARDS and non-ARDS patients
| RESULTS
Eighty-three patients with ARDS and 129 patients without ARDS
were recruited into the reported study. There were no significant differences in age, gender, pre-admission intubation rate, APACHE II score, duration of MV, length of ICU stay, and blood test results including WBC and NT-proBNP between the two groups ( Table 1) .
The mean CC16 concentration in the ARDS group was significantly higher than that in the non-ARDS group (54.44±19.62 vs 24.13±12.32 ng/mL, P=.001) (Figure 2A ). The differences in CRP, albumin, and Scr between the two groups were also statistically significant (all P<.05; Table 1 ). In addition, 7-and 28-day mortality for patients with ARDS was significantly greater than that in patients without ARDS.
The average levels of CC16 in patients with pneumonia (n=81) and without pneumonia (n=132) were 45.65ng/mL and 30.04ng/mL, respectively (P=.001) ( Figure 2B ). Univariate logistic regression analysis showed that factors in the diagnosis of ARDS included CRP, albumin, Scr, and serum CC16 (Table 2) .
Multivariate logistic regression analysis including CRP, albumin, Scr, and serum CC16 as variables showed that CC16 and CRP were independent factors that could be used in the diagnosis of ARDS (Table 3) . 
T A B L E 3
Multivariate logistic regression analysis of ARDS mild and moderate ARDS groups was not statistically significant ( Figure 4A ).
There was a significant negative correlation between serum CC16 concentration and PaO 2 /FiO 2 ratio in ARDS patients (r=−.272, P<.05; Figure 4B ). In the non-ARDS group, the correlation between serum CC16 concentration and PaO 2 /FiO 2 ratio was not significant (data not shown).
There was a significant difference in serum CC16 levels between survivors and non-survivors from the ARDS group at 7 days and 28 days ( Figure 5) . A close positive correlation was found between the serum CC16 levels and length of ICU stay among ARDS patients (r=.159,
P<.05).
However, similar association was not presented between the serum CC16 levels and the stay of hospital (r=.098, P>.05; Figure 6 ).
| DISCUSSION
In this study, elevated circulating CC16 levels identified ARDS and demonstrated a strong correlation with the severity of the disease as assessed by PaO 2 /FiO 2 ratio. Our analyses showed that CC16 was an independent factor that facilitated diagnosis of ARDS. In addition, CC16 levels differed significantly between survivors and nonsurvivors in ARDS patients and were correlated with ICU stay, but not hospital stay.
Increases in serum or plasma CC16 levels have been documented in studies of lung injuries caused by multiple etiologies, including systemic sclerosis, mechanical ventilation, air pollution, pulmonary sarcoidosis, and lung transplantation. 10, [14] [15] [16] [17] Our results demonstrating that CC16 rose significantly in ARDS patients were consistent with these studies. ARDS patients in the present study had more than double the median values of CC16 when compared with non-ARDS patients. While previous studies have demonstrated a relatively stable median CC16 value in normal controls (5-7 ng/mL), 12,13 the median CC16 value of non-ARDS patients in this study appeared to be higher (24.13±12.32 ng/mL). Some cases from the non-ARDS patient group had developed pulmonary diseases such as pneumonia, which may have caused an elevated production of CC16. 18 The compromised renal function indicated by an increase of Scr in some non-ARDS patients may be another reason accounting for the difference in the CC16 levels since a decreased glomerular filtration rate retards the clearance of CC16.
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Our results supported the notion that changes in circulating CC16 levels associated with chronic lung diseases were inconsistent with changes that occurred due to acute lung injury. Previous studies indicate that circulating CC16 levels are decreased in lung injures caused by agents like tobacco or hexavalent chromium. 20, 21 Chronic exposure to toxic agents causes a decline in the overall Clara cells located in terminal and respiratory bronchioles, leading to a relatively low production level of circulating CC16. Meanwhile, CC16 levels may vary due to differences in sample collection, measurement time points, and methods used in different studies. For example, a previous study of chemical-induced lung injury in rats has reported decreased serum CC16 levels after an initial transient Some studies have also revealed that CC16 levels in bronchoalveolar fluid (BALF) differ from blood CC16 levels. Following lung damage induced by mechanical ventilation (MV), the CC16 content is decreased in BALF but increased in the bloodstream. 15 The differing CC16 level changes are believed to be due to increased 24 However, a contrary conclusion was made in another clinical study where serum CC16 was indicated as one of the predictors of mortality in ARDS patients. 25 We speculate that different study populations result in this discrepancy in results.
A major strength of this study was the application of a blood biomarker for diagnosis of ARDS, which is often difficult to distinguish using clinical and radiographic criteria. Furthermore, we demonstrated that the serum CC16 level correlated closely with the severity of ARDS as assessed by PaO 2 /FiO 2 ratio. However, the current study had some limitations. First, the current study design may have the potential for selection bias. The discrepancy of basic diseases between the ARDS and non-ARDS group might limit the clinical application of this study. In addition, the mortality of ARDS group in this study seems to be higher than other reported studies. [1] [2] [3] This is probably due to the heterogeneity of different study populations. Second, the overall number of subjects was modest, limiting the statistical power of the study as well as our ability to control statistically for potential confounding factors in multivariate analysis. Third, we only monitored CC16 levels upon patient admission. The clinical course of CC16 during the hospitalization was not reported. Finally, we did not evaluate combined biomarkers for diagnosing ARDS. Therefore, it is necessary to evaluate the diagnostic and prognostic values of CC16 levels in large-scale, prospective clinical studies. In addition, the fact that blood test was not totally non-invasive and time-consuming might limit the clinical application.
In conclusion, serum CC16 level reflects the severity of ARDS and could help differentiate between different categories of ARDS.
However, it provides limited prognostic values for ARDS.
